Las Condes

291 / 320

695
REFERENCIAS BIBLIOGRÁFICAS
1. Back D, Koo S, Gibbons S, Wilkins E, Burger D, Shapiro
J, Marzolini C, editores. HIV Drug Interactions website.
Disponible en:
2. Tuset M, Miró JM, Codina C, Ribas J, editores. Guía de
interacciones farmacológicas en VIH. Disponible en: www.
3. Dickinson L, Khoo S, Back D. Pharmacokinetics and drug-drug
interactions of antiretrovirals: an update. Antiviral Res. 2010;
85:176–89.
4. McComsey G. Updated on mitochondrial toxicity of
antiretrovirals and its link to lipodystrophy. AIDS Reviews.
2002;4:140–7.
5. Ribera Esteban, Tuset Montse, Martín Maite, Del Cacho Elena.
Características de los fármacos antirretrovirales. Enferm
Infecc Microbiol Clin. 2011;29(5):362–391.
6. Ribera E. Toxicidad mitocondrial del tratamiento con
inhibidores de la transcriptasa inversa análogos de
nucleósidos/nucleótidos. Enf Infecc Microbiol Clin.
2004;3:48–56.
7. Domingo P, Vidal F. Toxicidad a largo plazo de los análogos
de nucleósidos/nucleótidos. Enf Infecc Microbiol Clin.
2006;5(Supp 1):22–9.
8. Dando TM, Scott LJ. Abacavir plus lamivudine. A review of
their combined use in the management of HIV infection.
Drugs. 2005;65:285-302.
9. Panel de Expertos de Gesida; Plan Nacional sobre el Sida.
Documento de consenso del Grupo de Estudio de Sida/Plan
Nacional sobre el Sida respecto al tratamiento antirretroviral
en adultos infectados por el virus de la inmunodeficiencia
humana (actualización enero 2016). Disponible: http://www.
guiasclinicas-2016-tar.pdf
10. Sabin CA, Reiss P, Ryom L, Phillips AN, Weber R, Law M, et al. Is
there continued evidence for an association between abacavir
usage and myocardial infarction risk in individuals with HIV?
A cohort collaboration. BMC Med. 2016 Mar 31;14(1):61.
11. Fichas técnicas europeas de los antirretrovirales.Disponible
en:
12. Saag MS. Emtricitabine, a new antiretroviral agent with
activity against HIV and hepatitis B virus. Clin Infect Dis.
2006;42:126–31.
13. Sachdeva RK1, Sharma A2, De D3, Malhi J4, Rewari BB4,
Singh S1, et al. Lamivudine-Induced Skin Rash Remains an
Underdiagnosed Entity in HIV: A Case Series from a Single
Center. J Int Assoc Provid AIDS Care. 2016 Mar-Apr;15(2):153-
8.
14. Johnson VA, Brun-Vézinet F,Clotet B,Günthard HF,Kuritzkes
DR,Pillay D,et al. Update of the Drug Resistance Mutations
in HIV-1: December 2009. Topics in HIV Medicine.
2009;17:138–45. Disponible en:
mutations/mutations figures.pdf.
15. Ribera E, Curran A. Papel actual de tenofovir en la clínica.
Enferm Infecc Microbiol Clin. 2008;26 Suppl 8:45–54.
16. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M.
Systematic review and meta-analysis: renal safety of tenofovir
disoproxil fumarate in HIV-infected patients. Clin Infect Dis.
2010;51:496-505.
17. De Clercq E. Tenofovir alafenamide (TAF) as the successor of
tenofovir disoproxil fumarate (TDF). Biochem Pharmacol.
2016 Apr 29. pii: S0006-2952(16)30069-7.
18. Antela A, Aguiar C, Compston J, Hendry BM, Boffito M, Mallon
P, et al. The role of tenofovir alafenamide in future HIV
management. HIV Med. 2016 May;17 Suppl 2:4-16.
19. Wilde MI, Langtry HD. Zidovudine. An update of its
pharmacodynamic and pharmacokinetic properties, and
therapeutic efficacy. Drugs. 1993;46:515-78.
20. Ribera E. Toxicidad mitocondrial del tratamiento con
inhibidores de la transcriptasa inversa análogos de
nucleósidos/nucleótidos. Enf Infecc Microbiol Clin.
2004;3:48–56.
21. Domingo P, Vidal F. Toxicidad a largo plazo de los análogos
de nucleósidos/nucleótidos. Enf Infecc Microbiol Clin.
2006;5(Supp 1):22–9.
22. Gaida R, Truter I, Grobler C, Kotze T, Godman B. A review of
trials investigating efavirenz-induced neuropsychiatric side
effects and the implications. Expert Rev Anti Infect Ther. 2016
Apr;14(4):377-88.
23. Curran A, Falcó V, Ribera E. Inhibidores de la proteasa. En:
Soriano V, González- Lahoz J, editors. Manual de sida. 8a
edición Barcelona: Publicaciones Permanyer; 2009. p.
167–202.
24. Boesecke CH, Cooper DA. Toxicity of HIV protease inhibitors:
clinical conside- rations. Curr Opin HIV AIDS. 2008;3:653–9.
25. Zeldin RK, Petruschke RA. Pharmacological and therapeutic
properties of ritonavir-boosted protease inhibitor therapy in
HIV-infected patients. J Anti- microb Chemother. 2004;53:4–
9.
26. Goncalves LS, Goncalves BM, de Andrade MA, Alves FR,
Junior AS. Drug interactions during periodontal therapy in
HIV-infected subjects. Mini Rev Med Chem. 2010;10:766–
72.
27. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP,
Graf JA, et al. Alprazolam-ritonavir interaction: Implications
for product labeling. Clin Pharmacol Ther. 2000;67:335–41.
28. Mur Lalaguna MA, Cobo Campos R, Hurtado Gomez MF,
Martinez Tutor MJ. Study of interactions between anti-
retroviral agents and concomitant drugs. Farm Hosp.
2003;27:84–92.
29. Hesse LM, von Moltke LL, Greenblatt DJ. Clinically important
drug interactions with zopiclone, zolpidem and zaleplon. CNS
Drugs. 2003;17:513–32.
30. De Kanter CT, Keuter M, van der Lee MJ, Koopmans PP, Burger
DM. Rhabdomyolysis in an HIV-infected patient with impaired
renal function concomitantly treated with rosuvastatin and
lopinavir/ritonavir. Antivir Ther. 2011;16: 435–7.
31. Nandwani R, Gourlay Y. Possible interaction between sildenafil
[FARMACOLOGÍA DE LOS ANTIRETROVIRALES - Q.F. Fernando Bernal]